Stockscreener 앱 받기
28.40
4.41%
1.20
시간 외 거래:
28.40
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes announces inaugural Alkermes Pathways APN Research Awards™ program - MSN
Big Picture: Can Alkermes plc stock outperform in a bear marketMarket Movers & Expert Approved Trade Ideas - baoquankhu1.vn
Alkermes outlines $1.73B–$1.84B 2026 revenue target as Avadel acquisition expands commercial reach - MSN
Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN
Alkermes plc (ALKS) Latest Stock News & Headlines - Yahoo Finance
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch - MarketBeat
Layoff Watch: Does Alkermes plc offer margin of safety2026 Volatility Report & Consistent Growth Equity Picks - baoquankhu1.vn
Holocene Advisors LP Cuts Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes appoints new CFO - MSN
How Alkermes Plc (ALKS) Affects Rotational Strategy Timing - Stock Traders Daily
Farallon Capital Management LLC Has $624,000 Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes plc Stock (ISIN: IE00B56GVS15) Under Pressure After Avadel Acquisition—Wells Fargo Raises - AD HOC NEWS
Alkermes plc $ALKS is Commodore Capital LP's 7th Largest Position - MarketBeat
Baker BROS. Advisors LP Boosts Holdings in Alkermes plc $ALKS - MarketBeat
Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN
Avoro Capital Advisors LLC Trims Position in Alkermes plc $ALKS - MarketBeat
Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Market Outlook: Will Alkermes plc outperform its industry peers2026 Summary & Long-Term Growth Plans - baoquankhu1.vn
Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - The Joplin Globe
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Alkermes to Present at the Stifel 2026 Virtual CNS Forum - BioSpace
ALKS Technical Analysis & Stock Price Forecast - Intellectia AI
Citigroup Inc. Sells 121,945 Shares of Alkermes plc $ALKS - MarketBeat
Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case (ALKS)? - simplywall.st
Rhenman & Partners Asset Management AB Buys 55,000 Shares of Alkermes plc $ALKS - MarketBeat
Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS - MarketBeat
Why analysts are rating Alkermes (ALKS) a buy - MSN
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks
Alkermes announces CEO succession plan - MSN
Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN
(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - Stocktwits
Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (ALKS) EVP Gaffin sells 4,068 shares and receives large option and RSU grants - Stock Titan
TD Asset Management Inc Sells 91,772 Shares of Alkermes plc $ALKS - MarketBeat
2,034-share Rule 144 sale by Alkermes insider (NASDAQ: ALKS) - Stock Titan
ALKS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celebrating LGBTQIA+ Mental Health Trailblazers - CSRwire
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance
Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan
Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan
5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan
Alkermes at TD Cowen: Strategic Shift to Sleep Medicine - Investing.com
Alkermes Plc (ALKS) Stock Analysis: Exploring A 45% Potential Upside In Biopharma - DirectorsTalk Interviews
American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes Releases Third Annual Corporate Responsibility Report - CSRwire
ALKSAlkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - mx.advfn.com
Alkermes plc $ALKS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Alkermes (ALKS) VP exercises RSUs and withholds 808 shares for tax - Stock Titan
Alkermes (ALKS) CCO logs RSU exercise and tax share withholding - Stock Titan
Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal - Stock Titan
Alkermes (ALKS) EVP Hopkinson converts 6,866 RSUs, withholds 3,049 shares for taxes - Stock Titan
Alkermes (ALKS) EVP Gaffin exercises RSUs, withholds 3,049 shares for tax - Stock Titan
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next - TipRanks
Alkermes plc $ALKS Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright lowers Alkermes stock price target on revenue guidance By Investing.com - Investing.com Canada
4 Analysts Have This To Say About Alkermes - Benzinga
2.02%
0.77%
자본화:
|
볼륨(24시간):